Scholarlink

Objectives <p>To assess the effectiveness and safety of sacituzumab govitecan in metastatic breast cancer (MBC), we performed a meta-analysis of randomized controlled trials comparing sacituzumab govitecan with chemotherapy.</p> Methods <p>We systematically searched multiple databases for relevant studies. Primary outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events (AEs). Data were analyzed using RevMan 5.3 software.</p> Results <p>Three studies were included after rigorous screening and quality assessment. Compared with chemotherapy, sacituzumab govitecan significantly prolonged PFS [HR 0.57; 95% CI 0.43, 0.77; <i>P</i> = 0.0002], improved OS [HR 0.64; 95% CI 0.48, 0.85; <i>P</i> = 0.002], and increased ORR [RR 2.84; 95% CI 1.27, 6.37; <i>P</i> = 0.01]. However, sacituzumab govitecan was associated with higher incidence of AEs (<i>P</i> &lt; 0.00001).</p> Conclusion <p>In this study, sacituzumab govitecan demonstrated improved PFS and OS compared to chemotherapy regimens in patients with MBC. Further research is required to validate its broad applicability and long-term treatment stability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A meta-analysis and systematic review of the first Trop-2-targeting antibody–drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer

  • 期刊论文

  • 发表日期：

    2025年7月7日

查看全文
  • Jue Wang,
  • Shengyou Lin,
  • Jialin Zhang,
  • Jingyang Su

摘要

Objectives

To assess the effectiveness and safety of sacituzumab govitecan in metastatic breast cancer (MBC), we performed a meta-analysis of randomized controlled trials comparing sacituzumab govitecan with chemotherapy.

Methods

We systematically searched multiple databases for relevant studies. Primary outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events (AEs). Data were analyzed using RevMan 5.3 software.

Results

Three studies were included after rigorous screening and quality assessment. Compared with chemotherapy, sacituzumab govitecan significantly prolonged PFS [HR 0.57; 95% CI 0.43, 0.77; P = 0.0002], improved OS [HR 0.64; 95% CI 0.48, 0.85; P = 0.002], and increased ORR [RR 2.84; 95% CI 1.27, 6.37; P = 0.01]. However, sacituzumab govitecan was associated with higher incidence of AEs (P < 0.00001).

Conclusion

In this study, sacituzumab govitecan demonstrated improved PFS and OS compared to chemotherapy regimens in patients with MBC. Further research is required to validate its broad applicability and long-term treatment stability.